52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Amgen Announces Phase 3 Candor Study Combining Kyprolis And Darzalex Meets Primary Endpoint Of Progression-Free Survival
Amgen Highlights New Data From Kyprolis (Carfilzomib) And Oncology Pipeline At IMW 2019
Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Biotechnology & Drugs
1 Amgen Center Dr
Robert A. Bradway
Chairman of the Board, President, Chief Executive Officer
David W. Meline
Executive Vice President, Chief Financial Officer
Executive Vice President of Global Commercial Operations
David M. Reese
Executive Vice President - Research and Development
Executive Vice President, Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.
The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.
The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.
A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)
Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.
Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.
A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.
A U.S. judge on Friday said patents relating to the Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.
A federal appeals court on Wednesday denied a request by Roche Holdings subsidiary Genentech Inc for a temporary order keeping a biosimilar version of its cancer drug Herceptin marketed by Amgen Inc off the U.S. market.
Amgen Inc <AMGN.O> on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.
Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.
Amgen Inc on Monday lost a bid to revive a lawsuit it filed seeking to block Coherus BioSciences Inc from selling a biosimilar version of its blockbuster chemotherapy drug Neulasta.
Roche Holdings subsidiary Genentech Inc has asked a federal appeals court to keep biosimilar versions of its cancer-fighting blockbusters Avastin and Herceptin off the U.S. market, after Amgen announced it had started selling the copies last week.
* AMGEN, NOVARTIS AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL RESEARCH PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION
* CO, AMGEN AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION Source text for Eikon: Further company coverage:
* AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE
An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly...
An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.
Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.